Monday's NASDAQ Top % Winners: ECYT, HAUP, SAPX, USAT
New York, NY - April 17, 2012 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Monday April 16th. The Nasdaq Composite fell 22.93 (-0.76%) to close at 2,988.40.
Endocyte, Inc. (NASDAQ:ECYT) shares soared $3.82 (100.53%) to end at $7.62
following news that Merck (NYSE: MRK) and Endocyte entered into an agreement to develop and commercialize Endocyte's novel investigational therapeutic candidate vintafolide (EC145). The stock is continuing its gains this morning in Tuesday’s trading.
Hauppauge Digital, Inc. (NASDAQ:HAUP) shares gained 0.37 (37.37%) to close at $1.36 without any official news. Hauppauge Digital Inc. is a developer of analog and digital television tuner and other products for the personal computer market. Through Hauppauge Computer Works, Inc., Hauppauge Digital Europe Sarl and PCTV Systems Sarl subsidiaries, the Company designs, develops, manufactures and markets analog.
Seven Arts Pictures PLC(NASDAQ:SAPX) shares gained 0.025 (20.83%)to close at $0.145 after the company said that it had terminated negotiations for a $3,000,000 convertible debenture, the proceeds of which were to have been used for reacquisition of approximately twelve of the Company's motion pictures controlled by an existing lender.
USA Technologies, Inc. (NASDAQ:USAT) shares rose 0.25 (18.25%) to end at $1.62 as the company projects to earn $300,000 on revenue of $7.5 million in its fiscal third-quarter, compared to a year ago loss of $940,170 on revenue of $5.5 million.
Get Free investor news and stock alerts at Investorideas.com
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks: Join: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising.
From time to time Investorideas.com buys shares in companies it features. As a policy, Investorideas.com does not short stocks
www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
Tuesday, April 17, 2012
Monday, April 16, 2012
Technology Incubator Los Angeles Syndicate of Technology (OTCQB: LAST) Reports Biotech Portfolio Company Receives IRB Approval
Santa Monica, CA - April 16, 2012 (Investorideas.com Newswire) Los Angeles Syndicate of Technology, Inc. (OTCQB: LAST), a publicly-traded venture fund and technology incubator, is pleased to announce that its portfolio company, Sanguine BioSciences, Inc. ("Sanguine"), has received approval from the Institutional Review Board ("IRB") to collect Biospecimen and Clinical Data from Patients diagnosed with Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease.
The approval by the IRB increases Sanguine's addressable customer markets by allowing Sanguine to collect blood, cerebral spinal fluid, and medical records from a broader base of potential patients. The IRB is a committee that has been formally designated to approve, monitor, and review biomedical and behavioral research involving humans.
Brian Neman, Founder and Chief Executive Officer, commented: "This marks Sanguine's most significant milestone to date. Not only does it enable us to serve many more research organizations and further the field of drug and biomarker research, but it will also significantly increase our capacity to empower those patients suffering from neurodegenerative and neurological disorders. We founded Sanguine with the vision of empowering patients and accelerating Personalized Medicine research and development, and this milestone is an important step to achieving that vision."
Sanguine currently serves over 60 customers through its global network of ten distributors in nine countries including customers like Harvard Medical School, Vanderbilt University, USC, UCLA, Lonza Group, Seracare, and Cambridge Bioscience. The company has surpassed $100,000 of revenue from USA, Canada, UK, France, Spain, Germany, Italy, Singapore, Japan, Korea, UK, Russia and Israel, with a current pipeline of over 160 purchase orders.
About Los Angeles Syndicate of Technology - www.last.vc
Los Angeles Syndicate of Technology, Inc. (OTC: LAST) is a publicly traded Business Development Company (BDC) operating as a venture fund and technology incubator that creates, builds, and invests in web and mobile technology companies. LAST develops digital media, social networking, and life sciences products in its technology incubator, and has a portfolio of six companies at different stages of development. LAST's mission is to foster technology innovation in Los Angeles by partnering with the most talented entrepreneurs of southern California and providing them with the capital, support and tools to bring their ideas to market and commercialize their products.
About Sanguine Biosciences, Inc. - sanguinebio.com
Sanguine Biosciences, Inc. ("Sanguine") is an international supplier of DNA data and bio-specimen to research organizations for the development of personalized medicines. Sanguine provides highly viable primary human cells and tissues to both the academic and industrial life science research communities through a new direct-to-patient platform. The current product offering spans customers' needs in the In Vitro Research & Development stage of Drug Development. Sanguine's vision is to develop into the global leader in high quality cells and tissues for life science research and development.
Forward-Looking Statements
Statements included in this release related to Los Angeles Syndicate of Technology, Inc. and its portfolio companies constitute or may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the inherent uncertainty of investing in early-stage technology companies, the technological and financial difficulties inherent in these activities, and the Company's ability to estimate accurately net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the Company's reports filed with the Securities and Exchange Commission.
Contact Information
Contact:
Los Angeles Syndicate of Technology, Inc.
Bryce Knight
(310) 694-0640
www.last.vc
Sanguine Biosciences accelerates Personalized Medicine discovery by providing biological and clinical data, including biospecimen and medical records to researchers, through a direct-to-patient platform that empowers patients in drug and biomarker research. Thousands of patients' biospecimen and medical information are needed to develop new drug and diagnostic, and the company's proprietary model enables it to collect, and ultimately provide patient biospecimen and clinical data much more quickly and less costly than current market standards.
An institutional review board (IRB), also known as an independent ethics committee (IEC) or ethical review board (ERB), is a committee that has been formally designated to approve, monitor, and review biomedical and behavioral research involving humans. In the United States, the Food and Drug Administration (FDA) and Department of Health and Human Services (specifically Office for Human Research Protections) regulations have empowered IRBs to approve, require modifications in planned research prior to approval, or disapprove research. IRBs are responsible for critical oversight functions for research conducted on human subjects that are scientific, ethical, and regulatory.
Disclaimer: Invesorideas.com sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising.
Disclosure: Invesorideas.com was compensated by LAST: OB for previous news release and content distribution unrelated to this release. Investorideas.com was not compensated for this news release distribution
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Santa Monica, CA - April 16, 2012 (Investorideas.com Newswire) Los Angeles Syndicate of Technology, Inc. (OTCQB: LAST), a publicly-traded venture fund and technology incubator, is pleased to announce that its portfolio company, Sanguine BioSciences, Inc. ("Sanguine"), has received approval from the Institutional Review Board ("IRB") to collect Biospecimen and Clinical Data from Patients diagnosed with Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease.
The approval by the IRB increases Sanguine's addressable customer markets by allowing Sanguine to collect blood, cerebral spinal fluid, and medical records from a broader base of potential patients. The IRB is a committee that has been formally designated to approve, monitor, and review biomedical and behavioral research involving humans.
Brian Neman, Founder and Chief Executive Officer, commented: "This marks Sanguine's most significant milestone to date. Not only does it enable us to serve many more research organizations and further the field of drug and biomarker research, but it will also significantly increase our capacity to empower those patients suffering from neurodegenerative and neurological disorders. We founded Sanguine with the vision of empowering patients and accelerating Personalized Medicine research and development, and this milestone is an important step to achieving that vision."
Sanguine currently serves over 60 customers through its global network of ten distributors in nine countries including customers like Harvard Medical School, Vanderbilt University, USC, UCLA, Lonza Group, Seracare, and Cambridge Bioscience. The company has surpassed $100,000 of revenue from USA, Canada, UK, France, Spain, Germany, Italy, Singapore, Japan, Korea, UK, Russia and Israel, with a current pipeline of over 160 purchase orders.
About Los Angeles Syndicate of Technology - www.last.vc
Los Angeles Syndicate of Technology, Inc. (OTC: LAST) is a publicly traded Business Development Company (BDC) operating as a venture fund and technology incubator that creates, builds, and invests in web and mobile technology companies. LAST develops digital media, social networking, and life sciences products in its technology incubator, and has a portfolio of six companies at different stages of development. LAST's mission is to foster technology innovation in Los Angeles by partnering with the most talented entrepreneurs of southern California and providing them with the capital, support and tools to bring their ideas to market and commercialize their products.
About Sanguine Biosciences, Inc. - sanguinebio.com
Sanguine Biosciences, Inc. ("Sanguine") is an international supplier of DNA data and bio-specimen to research organizations for the development of personalized medicines. Sanguine provides highly viable primary human cells and tissues to both the academic and industrial life science research communities through a new direct-to-patient platform. The current product offering spans customers' needs in the In Vitro Research & Development stage of Drug Development. Sanguine's vision is to develop into the global leader in high quality cells and tissues for life science research and development.
Forward-Looking Statements
Statements included in this release related to Los Angeles Syndicate of Technology, Inc. and its portfolio companies constitute or may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the inherent uncertainty of investing in early-stage technology companies, the technological and financial difficulties inherent in these activities, and the Company's ability to estimate accurately net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the Company's reports filed with the Securities and Exchange Commission.
Contact Information
Contact:
Los Angeles Syndicate of Technology, Inc.
Bryce Knight
(310) 694-0640
www.last.vc
Sanguine Biosciences accelerates Personalized Medicine discovery by providing biological and clinical data, including biospecimen and medical records to researchers, through a direct-to-patient platform that empowers patients in drug and biomarker research. Thousands of patients' biospecimen and medical information are needed to develop new drug and diagnostic, and the company's proprietary model enables it to collect, and ultimately provide patient biospecimen and clinical data much more quickly and less costly than current market standards.
- $100,000 in Revenue to Date
- $55,000 in Revenue in 2012
- 60 Customers including
- 10 distributiors selling to USA, Canada, UK France, Spain, Germany, Italy, Singapore, Japan, Korea, UK, Russia, Israel
- 161 open purchase orders
- The market size for patient and non-patient donor-derived biospecimens is estimated to be >$1B and estimated to grow to >$2.5B by 2015.
An institutional review board (IRB), also known as an independent ethics committee (IEC) or ethical review board (ERB), is a committee that has been formally designated to approve, monitor, and review biomedical and behavioral research involving humans. In the United States, the Food and Drug Administration (FDA) and Department of Health and Human Services (specifically Office for Human Research Protections) regulations have empowered IRBs to approve, require modifications in planned research prior to approval, or disapprove research. IRBs are responsible for critical oversight functions for research conducted on human subjects that are scientific, ethical, and regulatory.
Disclaimer: Invesorideas.com sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising.
Disclosure: Invesorideas.com was compensated by LAST: OB for previous news release and content distribution unrelated to this release. Investorideas.com was not compensated for this news release distribution
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Medical Technology Stock Alert; PositiveID Corporation's (OTCBB:PSID) iglucose Mobile Health Solution Makes Significant Progress With Active Customer Deployments
DELRAY BEACH, Fla. - April 16, 2012 (Investorideas.com newswire) - PositiveID Corporation (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense, today announced significant progress with the initial deployment of its FDA-cleared iglucose(TM) mobile health system for diabetes management. The iglucose System is currently being trialed by a leading health insurer, a large consumer healthcare products company and an international telecommunications provider. The Company also recently announced the use of iglucose in a trial with a leading global pharmaceutical company.
PositiveID's FDA-cleared iglucose System is a convenient and easy-to-use wireless solution designed to empower individuals with diabetes to become more engaged in the self-management of their condition. iglucose seamlessly communicates blood glucose data from glucometers to the iglucose diabetes management portal, where reports are generated and can be shared with family members and healthcare professionals, making it possible to improve care in a cost-effective manner. The iglucose system communicates according to the user's preferences via online access, email, fax or SMS text. iglucose eliminates the burden of keeping logbooks and enables individuals with diabetes to proactively take control of their glucose levels and treatment regimens. iglucose does not require the use of a cell phone or a wireless plan.
"Many large organizations are currently trialing iglucose, from one of the largest health insurers in the U.S., to one of the largest consumer healthcare products companies in the world," stated William J. Caragol, PositiveID's Chairman and CEO. "We are providing this progress report following our announcement last week that we made iglucose available for pre-order for consumers. We received a very positive response and therefore want to update the investor community as well as those with diabetes about our next steps."
The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan(R), Abbott FreeStyle(R), Bayer Contour (R), and Nipro Diagnostic(TM) True(TM) monitoring systems to a secure database via wireless cellular technology. PositiveID is continually adding to this list of supported glucose meters. For more information on iglucose, visit www.iglucose.com.
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
DELRAY BEACH, Fla. - April 16, 2012 (Investorideas.com newswire) - PositiveID Corporation (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense, today announced significant progress with the initial deployment of its FDA-cleared iglucose(TM) mobile health system for diabetes management. The iglucose System is currently being trialed by a leading health insurer, a large consumer healthcare products company and an international telecommunications provider. The Company also recently announced the use of iglucose in a trial with a leading global pharmaceutical company.
PositiveID's FDA-cleared iglucose System is a convenient and easy-to-use wireless solution designed to empower individuals with diabetes to become more engaged in the self-management of their condition. iglucose seamlessly communicates blood glucose data from glucometers to the iglucose diabetes management portal, where reports are generated and can be shared with family members and healthcare professionals, making it possible to improve care in a cost-effective manner. The iglucose system communicates according to the user's preferences via online access, email, fax or SMS text. iglucose eliminates the burden of keeping logbooks and enables individuals with diabetes to proactively take control of their glucose levels and treatment regimens. iglucose does not require the use of a cell phone or a wireless plan.
"Many large organizations are currently trialing iglucose, from one of the largest health insurers in the U.S., to one of the largest consumer healthcare products companies in the world," stated William J. Caragol, PositiveID's Chairman and CEO. "We are providing this progress report following our announcement last week that we made iglucose available for pre-order for consumers. We received a very positive response and therefore want to update the investor community as well as those with diabetes about our next steps."
The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan(R), Abbott FreeStyle(R), Bayer Contour (R), and Nipro Diagnostic(TM) True(TM) monitoring systems to a secure database via wireless cellular technology. PositiveID is continually adding to this list of supported glucose meters. For more information on iglucose, visit www.iglucose.com.
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.aspVisit the company profile: http://www.investorideas.com/CO/PSID/
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Pacific Therapeutics Ltd. (PT.CNSX) PROGRESS OF CLINICAL DEVELOPMENT
PROGRESS OF CLINICAL DEVELOPMENT VANCOUVER, BRITISH COLUMBIA – April 16, 2012 (Investorideas.com Newswire) Pacific Therapeutics Ltd. (PT.CNSX) (the “Company”) is pleased to provide an update on the progress of the clinical development of PTL-202. As previously announced the Company has engaged CRBIO of India to conduct a drug drug interaction study of PTL-202 and its components. CRBio has submitted the PTL-202 drug-drug interaction clinical trial protocol to the Central Drugs Standard Control Organization Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, New Delhi, India.
The clinical study protocol is currently being reviewed by the Central Drugs Standard Control Organization ( India 's pharmaceutical regulatory authority). The study will be conducted once this regulatory approval is received, which is expected this quarter. The study protocol calls for dosing of 12 normal healthy adult males. This an open label, non randomized, three treatment, three period single dose study. Once enrolment is completed the study should only take 1 month to complete.
The lack of any drug drug interaction will be a positive result and signal the continued clinical development of PTL-202. CRBio is 'full service' contract research organization. It is set up in a centrally located area in Hyderabad India . The facility is spread over 20,000 sq.ft. in well laid out areas with operations such as Clinical, Bioanalytical, Pharmacokinetic & Statistical, QA & RA , QC . With 4 full time doctors plus paramedical staff, clinics consist of 72 beds and CRBio has a 3,000 volunteer database and a state of the art bioanalytical laboratory. CRBio as an independent contractor has completed over 150 BA/BE (Bioavailability Bioequivalence) projects similar to the PTL-202 drug drug interaction study.
ABOUT PACIFIC THERAPEUTICS LTD. (http://www.pacifictherapeutics.com/)
Pacific Therapeutics Ltd is a clinical stage specialty pharmaceutical company focused on the identification and development of drug candidates to treat diseases of excessive scarring (fibrosis). The company's lead drug candidate PTL-202 is a combination of Pentoxifylline (a FDA approved drug used for treating intermittent claudication) and N-Acetyl-Cysteine (NAC) an amino acid and an extremely potent and important antioxidant. PTL-202 is currently being reviewed for initial trials in humans which are expected to commence in 2012. PTL-202 a combination of approved drugs focused on treating fibrosis such as Idiopathic Pulmonary Fibrosis and Liver Cirrhosis.
The Company's strategy includes reformulating approved drugs to increase efficacy and patient compliance, completing the further clinical testing, manufacturing and other regulatory requirements sufficient to seek marketing authorizations. This strategy may reduce the risk, time and cost of developing therapies for fibrosis by avoiding the risks associated with basic research and using compounds with unknown safety and toxicity profiles.
FORWARD LOOKING STATEMENTS Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events.
This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Readers should not place undue reliance on the Company's forward-looking statements, as the Company's actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors affect the Company's business, or if the Company's estimates or assumptions prove inaccurate. Therefore, the Company cannot provide any assurance that such forward-looking statements will materialize. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.
On Behalf of the Board of Directors /s/ Doug Unwin Douglas H. Unwin, CEO & President
(604) 738-1049
Friday, April 13, 2012
Water Stocks Investor Alert: Primo Water (PRMW) Top Gainer on NASDAQ in Morning Trading
New York, NY - April 13, 2012 (Investorideas.com water stocks newswire) Investorideas.com, a leader in sector research including water stocks issues a trading alert for water stock Primo Water Corporation (NasdaqGM:PRMW), trading at $2.07, up 0.47(29.53%) 10:46AM EDT on over 2.4 Million shares. Primo is the top percentage gainer on NASDAQ in the morning session.
The Company reported today it has received a commitment from a senior lender to enter into a new long-term $20 million senior revolving credit facility. Also, the Company expects to close a term loan for up to an additional $15 million with a separate lender, secured by certain fixed assets of the Company.
About Primo Water Corporation
Primo Water Corporation (Nasdaq:PRMW) is a leading provider of water dispensers, environmentally responsible bulk bottled water and premier sparkling beverage appliances sold through major retailers throughout the United States and Canada. Learn more about Primo Water at www.primowater.com and www.primoflavorstation.com.
Linkedin.com: Water Stocks - Social network for investors following water stocks
Research water stocks with the global water stocks directory including TSX, OTC, NASDAQ, NYSE, AIM, HONG KONG, ASX water stocks
Sign up for free investor newsletters and water stock alerts at Investor Ideas
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by news submissions and online advertising. Compensation Disclosure and disclaimers: www.InvestorIdeas.com/About/Disclaimer.asp, http://www.investorideas.com/About/News/Clientspecifics.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For More Information Contact:
Web Site: www.InvestorIdeas.com www.water-stocks.com
800 665 0411
New York, NY - April 13, 2012 (Investorideas.com water stocks newswire) Investorideas.com, a leader in sector research including water stocks issues a trading alert for water stock Primo Water Corporation (NasdaqGM:PRMW), trading at $2.07, up 0.47(29.53%) 10:46AM EDT on over 2.4 Million shares. Primo is the top percentage gainer on NASDAQ in the morning session.
The Company reported today it has received a commitment from a senior lender to enter into a new long-term $20 million senior revolving credit facility. Also, the Company expects to close a term loan for up to an additional $15 million with a separate lender, secured by certain fixed assets of the Company.
About Primo Water CorporationPrimo Water Corporation (Nasdaq:PRMW) is a leading provider of water dispensers, environmentally responsible bulk bottled water and premier sparkling beverage appliances sold through major retailers throughout the United States and Canada. Learn more about Primo Water at www.primowater.com and www.primoflavorstation.com.
Research water stocks with the global water stocks directory including TSX, OTC, NASDAQ, NYSE, AIM, HONG KONG, ASX water stocks
Sign up for free investor newsletters and water stock alerts at Investor Ideas
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by news submissions and online advertising. Compensation Disclosure and disclaimers: www.InvestorIdeas.com/About/Disclaimer.asp, http://www.investorideas.com/About/News/Clientspecifics.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For More Information Contact:
Web Site: www.InvestorIdeas.com www.water-stocks.com
800 665 0411
Solar News: Salamon Group (OTCQB:SLMU) Completes Acquisition of Eco Energy Solutions of Australia and Appoints CEO Gary Yost to the Board of Directors of Salamon Group
LAS VEGAS, NV - April 13, 2012 (Investorideas.com renewable energy newswire) Salamon Group, Inc. (OTCQB: SLMU) announces that Sunlogics Power, its wholly owned subsidiary (www.sunlogicspowerfund.com), has successfully completed final closing documentation on Eco Energy Solutions Pty Limited (ECO) in exchange for 8 million shares of Salamon Group, Inc. (SGI). The transaction was valued at 8 million dollars.
Eco Energy is a successful Australian-based renewable energy company with revenues of approximately 13 million USD and an EBITA of $0.960 million for year ending 2011 and ECO is on track to exceed those numbers this year. This transaction is immediately accretive to Salamon Group. ECO shareholders have agreed to take secured debt against ECO and its assets until the Authorized capital in Salamon Group, Inc. has been increase to allow for the conversion into equity.
At the end of February 2012 Eco Energy had installed 2,630 domestic systems through its contracts which started in May 2010. The contracts cover all of the state of Tasmania and all of central Victoria.
Michael Matvieshen, CEO, Salamon Group, commented, "Eco brings value to our shareholders in several ways which include the experience it has in the southern hemisphere for renewable energy project development. With its vast array of contacts, it opens up a very large and lucrative market for us. Together we expect to have a real and competitive footprint in these rapidly expanding markets."
Additionally, Mr. Gary Yost, the Managing Director of Eco Energy, will assume a seat on the Board of Directors of Sunlogics Power Fund and Salamon Group. Mr. Yost brings industry experience and contacts that have allowed him to create a "one stop shop" methodology to take any project from conception through to design, supply, installation and commissioning. Mr. Yost has overseen the growth of a client base that includes all levels of government, private and public utilities and projects that meet the needs of commercial and individual clients, as well as a number of overseas projects.
Mr. Matvieshen, CEO, Salamon Group, further stated, "It's excellent to be working with Gary as he has built a company from the ground up. He understands the business challenges and will be a valuable member of our 'go to market' team worldwide."
ECO will in turn benefit from SGIs' business synergies, such as accessing the CTIEC relationship and the financing investment banking relationships that are already in place at SGI.
ABOUT ECO ENERGY SOLUTIONS
Eco Energy Solutions specializes in the Design, Supply, Installation, Commissioning and Maintenance of Solar PV, Solar Hot water, Wind Turbine and Micro/Mini Hydro projects. Eco Energy Solutions (Australia) Pty Ltd is a very dynamic Australian business specializing in the Renewable Energy sector. We provide a full Integrated Systems House Solution service to all aspects of the Renewable Energy industry. We are involved in the leading projects in Australia in this sector. http://www.ecoenergysolutions.com.au/
About Salamon Group
Salamon Group, Inc. and its Sunlogics Power Fund Management, Inc. division, is a solar and renewable energy company specializing in the acquisition, construction and management of renewable energy power projects and companies. It is a project-acquiring partner of Sunlogics Plc and its subsidiary as well as other third party project developers. The Company also takes positions in other solar and renewable energy project producing companies that are a strategic fit within the Company's overall strategy.
For further information, Orsay Groupe, Inc. 305-515-8077 and/or visit: http://www.sunlogicspowerfund.com/ www.sunlogics.com
SLMU cautions that statements made in press releases constitute forward-looking statements, and makes no guarantees of future performances and actual results/developments may differ materially from projections in forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the time statements are made.
Contact:
Orsay Groupe, Inc.
William J. Nalley
305-515-8077
williamjnalley@yahoo.com
Published on Investorideas.com newswire
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp. Disclosure: SLMU is a paid customer on Investorideas,com , publishing press releases and company content on Investorideas.com and our syndicated blogs and global partners effective March 14 ,2012 (three months: one thousand per month and nine thousand equivalent in 144 shares)
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
LAS VEGAS, NV - April 13, 2012 (Investorideas.com renewable energy newswire) Salamon Group, Inc. (OTCQB: SLMU) announces that Sunlogics Power, its wholly owned subsidiary (www.sunlogicspowerfund.com), has successfully completed final closing documentation on Eco Energy Solutions Pty Limited (ECO) in exchange for 8 million shares of Salamon Group, Inc. (SGI). The transaction was valued at 8 million dollars.
Eco Energy is a successful Australian-based renewable energy company with revenues of approximately 13 million USD and an EBITA of $0.960 million for year ending 2011 and ECO is on track to exceed those numbers this year. This transaction is immediately accretive to Salamon Group. ECO shareholders have agreed to take secured debt against ECO and its assets until the Authorized capital in Salamon Group, Inc. has been increase to allow for the conversion into equity.
At the end of February 2012 Eco Energy had installed 2,630 domestic systems through its contracts which started in May 2010. The contracts cover all of the state of Tasmania and all of central Victoria.
Michael Matvieshen, CEO, Salamon Group, commented, "Eco brings value to our shareholders in several ways which include the experience it has in the southern hemisphere for renewable energy project development. With its vast array of contacts, it opens up a very large and lucrative market for us. Together we expect to have a real and competitive footprint in these rapidly expanding markets."
Additionally, Mr. Gary Yost, the Managing Director of Eco Energy, will assume a seat on the Board of Directors of Sunlogics Power Fund and Salamon Group. Mr. Yost brings industry experience and contacts that have allowed him to create a "one stop shop" methodology to take any project from conception through to design, supply, installation and commissioning. Mr. Yost has overseen the growth of a client base that includes all levels of government, private and public utilities and projects that meet the needs of commercial and individual clients, as well as a number of overseas projects.
Mr. Matvieshen, CEO, Salamon Group, further stated, "It's excellent to be working with Gary as he has built a company from the ground up. He understands the business challenges and will be a valuable member of our 'go to market' team worldwide."
ECO will in turn benefit from SGIs' business synergies, such as accessing the CTIEC relationship and the financing investment banking relationships that are already in place at SGI.
ABOUT ECO ENERGY SOLUTIONS
Eco Energy Solutions specializes in the Design, Supply, Installation, Commissioning and Maintenance of Solar PV, Solar Hot water, Wind Turbine and Micro/Mini Hydro projects. Eco Energy Solutions (Australia) Pty Ltd is a very dynamic Australian business specializing in the Renewable Energy sector. We provide a full Integrated Systems House Solution service to all aspects of the Renewable Energy industry. We are involved in the leading projects in Australia in this sector. http://www.ecoenergysolutions.com.au/
About Salamon Group
Salamon Group, Inc. and its Sunlogics Power Fund Management, Inc. division, is a solar and renewable energy company specializing in the acquisition, construction and management of renewable energy power projects and companies. It is a project-acquiring partner of Sunlogics Plc and its subsidiary as well as other third party project developers. The Company also takes positions in other solar and renewable energy project producing companies that are a strategic fit within the Company's overall strategy.
For further information, Orsay Groupe, Inc. 305-515-8077 and/or visit: http://www.sunlogicspowerfund.com/ www.sunlogics.com
SLMU cautions that statements made in press releases constitute forward-looking statements, and makes no guarantees of future performances and actual results/developments may differ materially from projections in forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the time statements are made.
Contact:
Orsay Groupe, Inc.
William J. Nalley
305-515-8077
williamjnalley@yahoo.com
Published on Investorideas.com newswire
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp. Disclosure: SLMU is a paid customer on Investorideas,com , publishing press releases and company content on Investorideas.com and our syndicated blogs and global partners effective March 14 ,2012 (three months: one thousand per month and nine thousand equivalent in 144 shares)
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Medical Technology Stock Alert; PositiveID Corporation (OTCBB:PSID) Offers iglucose Mobile Health Solution to Rural Healthcare Providers
DELRAY BEACH, Fla. - April 13, 2012 (Investorideas.com newswire) - PositiveID Corporation (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense, today announced it is offering its FDA-cleared iglucose(R) mobile health system for diabetes management to rural healthcare providers, who care for approximately 62 million people in the U.S. To promote its awareness among rural healthcare providers, iglucose will be demonstrated at the National Rural Health Association's 35th Annual Rural Health Conference from April 17-20, 2012, at the Hyatt Regency Denver, Colorado Convention Center, in conjunction with healthcare solutions provider Merge-MD in booth #213.
PositiveID's FDA-cleared iglucose System uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By seamlessly communicating data from glucometers to the iglucose diabetes management portal, glucose readings can be shared with family members and healthcare professionals, making it possible to improve care in a cost-effective manner. The iglucose system creates a variety of reports and communicates according to the user's preferences via online access, email, fax or SMS text. iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. iglucose does not require the use of a cell phone or a wireless plan.
"The response to iglucose from our customers and prospects is overwhelming. iglucose is a perfect rural tele-health solution for people with diabetes and those who care for them," stated Scott Griffith, Chief Operating Officer of Merge-MD. "Most people with diabetes need to be seen every 90 days, which can be a challenge when many endocrinologists and diabetes educators are located in major cities, not small towns. With iglucose, information can be shared at any time with healthcare professionals who are hundreds of miles away."
The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan(R), Abbott FreeStyle(R), Bayer Contour (R), and Nipro Diagnostic(TM) True(TM) monitoring systems to a secure database via wireless cellular technology. PositiveID is continually adding to this list of supported glucose meters. For more information on iglucose, visit www.iglucose.com.
The National Rural Health Association's 35th Annual Rural Health Conference nation's largest rural health conference, created for all of those with an interest in rural health care, including rural health practitioners, hospital administrators, clinic directors and lay health workers, social workers, state and federal health employees, academics, community members, and all others interested in rural health care.
About Merge-MD
Merge-MD is an innovative healthcare solutions company founded and focused on how health information technology (including electronic health and medical records), processes and people can work together to advance the quality of healthcare. Merge-MD believes electronic health records should follow patients in real time so healthcare providers can make fast, safe decisions, reduce costs by eliminating redundant care and improve the quality of care overall.
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
DELRAY BEACH, Fla. - April 13, 2012 (Investorideas.com newswire) - PositiveID Corporation (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense, today announced it is offering its FDA-cleared iglucose(R) mobile health system for diabetes management to rural healthcare providers, who care for approximately 62 million people in the U.S. To promote its awareness among rural healthcare providers, iglucose will be demonstrated at the National Rural Health Association's 35th Annual Rural Health Conference from April 17-20, 2012, at the Hyatt Regency Denver, Colorado Convention Center, in conjunction with healthcare solutions provider Merge-MD in booth #213.
PositiveID's FDA-cleared iglucose System uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By seamlessly communicating data from glucometers to the iglucose diabetes management portal, glucose readings can be shared with family members and healthcare professionals, making it possible to improve care in a cost-effective manner. The iglucose system creates a variety of reports and communicates according to the user's preferences via online access, email, fax or SMS text. iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. iglucose does not require the use of a cell phone or a wireless plan.
"The response to iglucose from our customers and prospects is overwhelming. iglucose is a perfect rural tele-health solution for people with diabetes and those who care for them," stated Scott Griffith, Chief Operating Officer of Merge-MD. "Most people with diabetes need to be seen every 90 days, which can be a challenge when many endocrinologists and diabetes educators are located in major cities, not small towns. With iglucose, information can be shared at any time with healthcare professionals who are hundreds of miles away."
The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan(R), Abbott FreeStyle(R), Bayer Contour (R), and Nipro Diagnostic(TM) True(TM) monitoring systems to a secure database via wireless cellular technology. PositiveID is continually adding to this list of supported glucose meters. For more information on iglucose, visit www.iglucose.com.
The National Rural Health Association's 35th Annual Rural Health Conference nation's largest rural health conference, created for all of those with an interest in rural health care, including rural health practitioners, hospital administrators, clinic directors and lay health workers, social workers, state and federal health employees, academics, community members, and all others interested in rural health care.
About Merge-MD
Merge-MD is an innovative healthcare solutions company founded and focused on how health information technology (including electronic health and medical records), processes and people can work together to advance the quality of healthcare. Merge-MD believes electronic health records should follow patients in real time so healthcare providers can make fast, safe decisions, reduce costs by eliminating redundant care and improve the quality of care overall.
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.aspVisit the company profile: http://www.investorideas.com/CO/PSID/
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Thursday, April 12, 2012
Solar News: Salamon Group Inc. (OTCQB:SLMU) Appoints NCP Northland Capital Partners Inc. International as Their Designated Investment Banker
LAS VEGAS, NV - April 12, 2012 (Investorideas.com renewable energy newswire) Salamon Group, Inc. (OTCQB: SLMU) a leading edge green energy company, is pleased to announce that it has retained NCP Northland Capital Partners, Inc. (NCP) as the company's investment banker. NCP will assist with the Company's next round of financing, as well as, advise and assist with its needs including transitioning to more senior exchanges such as the NASDAQ and TSX.
NCP Northland Capital Partners Inc. (NCP) is an employee-owned securities firm that is a client-focused financial services firm targeting fast-growing companies in the small and mid-cap markets. NCP has completed over $2.2 Billion of funding for its clients. Some of these clients include: New Zealand Energy, Innergex Renewable Energy, Finavera Wind Energy, Nextraction Energy, and AMP Solar Group.
Michael Matvieshen, CEO Salamon Group, stated, "We are very pleased with this agreement, NCP employs two of the top rated special situations analysts in the 'Clean Tech' sector and their understanding of our sector will complement our international and global business." Mr. Matvieshen went on to say, "Additionally, because NCP is a full service Investment Bank, they have abilities from arranging funding to sponsor companies in graduating listings to higher exchanges which are important next steps for us."
About NCP Northland Capital Partners:
NCP Northland Capital Partners (USA) Inc. ("NCP USA"), a member of FINRA, is an affiliated company to NCP Northland Capital Partners Inc. ("NCP Canada"). NCP USA is head quartered in Toronto and provides U.S. domiciled institutional customers with NCP Canada produced research on Canadian listed issuers in the following areas: mining and resources, industrial and infrastructure, clean technology and technology, telecom and media, and life sciences and special situations. Through NCP Canada's exchange memberships, NCP USA can provide U.S. institutional customers with direct execution of Canadian exchange listed issuers. NCP USA can also provide U.S. institutional customers with new issue and private placement opportunities.
About Salamon Group
Salamon Group, Inc. and its Sunlogics Power Fund Management, Inc. division, is a solar and renewable energy company specializing in the acquisition, construction and management of renewable energy power projects and companies. It is a project-acquiring partner of Sunlogics Plc and its subsidiary as well as other third party project developers. The Company also takes positions in other solar and renewable energy project producing companies that are a strategic fit within the Company's overall strategy.
For further information, Orsay Groupe, Inc. 305-515-8077 and/or visit: http://www.sunlogicspowerfund.com/ www.sunlogics.com
SLMU cautions that statements made in press releases constitute forward-looking statements, and makes no guarantees of future performances and actual results/developments may differ materially from projections in forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the time statements are made.
Contact:
Orsay Groupe, Inc.
William J. Nalley
305-515-8077
williamjnalley@yahoo.com
Published on Investorideas.com newswire
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp. Disclosure: SLMU is a paid customer on Investorideas,com , publishing press releases and company content on Investorideas.com and our syndicated blogs and global partners effective March 14 ,2012 (three months: one thousand per month and nine thousand equivalent in 144 shares)
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
LAS VEGAS, NV - April 12, 2012 (Investorideas.com renewable energy newswire) Salamon Group, Inc. (OTCQB: SLMU) a leading edge green energy company, is pleased to announce that it has retained NCP Northland Capital Partners, Inc. (NCP) as the company's investment banker. NCP will assist with the Company's next round of financing, as well as, advise and assist with its needs including transitioning to more senior exchanges such as the NASDAQ and TSX.
NCP Northland Capital Partners Inc. (NCP) is an employee-owned securities firm that is a client-focused financial services firm targeting fast-growing companies in the small and mid-cap markets. NCP has completed over $2.2 Billion of funding for its clients. Some of these clients include: New Zealand Energy, Innergex Renewable Energy, Finavera Wind Energy, Nextraction Energy, and AMP Solar Group.
Michael Matvieshen, CEO Salamon Group, stated, "We are very pleased with this agreement, NCP employs two of the top rated special situations analysts in the 'Clean Tech' sector and their understanding of our sector will complement our international and global business." Mr. Matvieshen went on to say, "Additionally, because NCP is a full service Investment Bank, they have abilities from arranging funding to sponsor companies in graduating listings to higher exchanges which are important next steps for us."
About NCP Northland Capital Partners:
NCP Northland Capital Partners (USA) Inc. ("NCP USA"), a member of FINRA, is an affiliated company to NCP Northland Capital Partners Inc. ("NCP Canada"). NCP USA is head quartered in Toronto and provides U.S. domiciled institutional customers with NCP Canada produced research on Canadian listed issuers in the following areas: mining and resources, industrial and infrastructure, clean technology and technology, telecom and media, and life sciences and special situations. Through NCP Canada's exchange memberships, NCP USA can provide U.S. institutional customers with direct execution of Canadian exchange listed issuers. NCP USA can also provide U.S. institutional customers with new issue and private placement opportunities.
About Salamon Group
Salamon Group, Inc. and its Sunlogics Power Fund Management, Inc. division, is a solar and renewable energy company specializing in the acquisition, construction and management of renewable energy power projects and companies. It is a project-acquiring partner of Sunlogics Plc and its subsidiary as well as other third party project developers. The Company also takes positions in other solar and renewable energy project producing companies that are a strategic fit within the Company's overall strategy.
For further information, Orsay Groupe, Inc. 305-515-8077 and/or visit: http://www.sunlogicspowerfund.com/ www.sunlogics.com
SLMU cautions that statements made in press releases constitute forward-looking statements, and makes no guarantees of future performances and actual results/developments may differ materially from projections in forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the time statements are made.
Contact:
Orsay Groupe, Inc.
William J. Nalley
305-515-8077
williamjnalley@yahoo.com
Published on Investorideas.com newswire
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp. Disclosure: SLMU is a paid customer on Investorideas,com , publishing press releases and company content on Investorideas.com and our syndicated blogs and global partners effective March 14 ,2012 (three months: one thousand per month and nine thousand equivalent in 144 shares)
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Wednesday's NASDAQ Winners: NEWL, YRCW, TZOO, PWAV
New York, NY - April 12, 2012 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Wednesday April 11th. The Nasdaq Composite recovered 25.24 (0.84%) to close at 3,016.46.
NewLead Holdings Ltd. (NASDAQ:NEWL) continued to move up and added 78.80% to close at $4.47. The stock has soared over 228% in the past one week and made a new 52-week high of $5.23 in the previous trading session. Recently, the company announced further progress in the restructuring process with the redelivery of four dry bulk vessels, the" Australia", the " Brazil", the " China" and the"Grand Rodosi", to their respective owners, which are affiliates ofLemissoler Maritime Company W.L.L.
YRC Worldwide, Inc. (NASDAQ:YRCW) shares climbed 33.19% and closed at $6.14, bouncing back from a 40% fall in the past one week. On April 5, 2012, the company said that the company has received multiple bids for more than 60 facilities put up for sale via a sealed-bid auction and is analyzing those offers. No final decisions have been made on the properties.
Travelzoo Inc. (NASDAQ:TZOO) shares increased 28.49% and closed at $27.06 in yesterday's session after on reports that the company is planning to sell itself. Reuters reported that possible buyers could be Google, Amazon or travel website Odigeo. The company is also planning to hire a financial adviser. In the last one year, the shares of the company has plummeted 70%. Travelzoo is a global Internet media company. In January, the company posted its fourth-quarter earnings which soared 70% owing to double-digit subscriber and revenue growth.
Powerwave Technologies, Inc. (NASDAQ:PWAV) shares jumped 22.16% and closed at $2.26. The stock has outperformed wider markets with double digit monthly gains. Although the company was involved in an investor lawsuit that had a negative impact on the stock price in the past, the situation seems to have reversed in the last month or so, owing to expectations that the company will be able to sail through this rough environment.
Get Free investor news and stock alerts at Investorideas.com
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411 - Source - www.Investorideas.com
New York, NY - April 12, 2012 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Wednesday April 11th. The Nasdaq Composite recovered 25.24 (0.84%) to close at 3,016.46.
NewLead Holdings Ltd. (NASDAQ:NEWL) continued to move up and added 78.80% to close at $4.47. The stock has soared over 228% in the past one week and made a new 52-week high of $5.23 in the previous trading session. Recently, the company announced further progress in the restructuring process with the redelivery of four dry bulk vessels, the" Australia", the " Brazil", the " China" and the"Grand Rodosi", to their respective owners, which are affiliates ofLemissoler Maritime Company W.L.L.
YRC Worldwide, Inc. (NASDAQ:YRCW) shares climbed 33.19% and closed at $6.14, bouncing back from a 40% fall in the past one week. On April 5, 2012, the company said that the company has received multiple bids for more than 60 facilities put up for sale via a sealed-bid auction and is analyzing those offers. No final decisions have been made on the properties.
Travelzoo Inc. (NASDAQ:TZOO) shares increased 28.49% and closed at $27.06 in yesterday's session after on reports that the company is planning to sell itself. Reuters reported that possible buyers could be Google, Amazon or travel website Odigeo. The company is also planning to hire a financial adviser. In the last one year, the shares of the company has plummeted 70%. Travelzoo is a global Internet media company. In January, the company posted its fourth-quarter earnings which soared 70% owing to double-digit subscriber and revenue growth.
Powerwave Technologies, Inc. (NASDAQ:PWAV) shares jumped 22.16% and closed at $2.26. The stock has outperformed wider markets with double digit monthly gains. Although the company was involved in an investor lawsuit that had a negative impact on the stock price in the past, the situation seems to have reversed in the last month or so, owing to expectations that the company will be able to sail through this rough environment.
Get Free investor news and stock alerts at Investorideas.com
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411 - Source - www.Investorideas.com
Healthcare investors and Biotech Traders Podcast: Company Spotlight on Sirona Biochem (TSX-V: SBM, OTC: SRBCF)
New York, New York � April 12, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks releases an investor podcast for biotech traders and investors with a company spotlight on a small biotech company making headway in the diabetes and obesity market with its core technology.
Sirona Biochem Corp (TSX-V: SBM , OTC: SRBCF), is a company using Carbohydrate-based molecules to develop Sodium Glucose Transporter (SGLT) inhibitors for Type 2 diabetes and obesity as one of its key products in its pipeline.
Listen to Podcast
About Sirona Biochem Corp (www.sironabiochem.com)
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Research biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure- Investorideas.com and its affiliate news and email partners were compensated six thousand for news distribution and publishing online and to optin subscribers
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com
New York, New York � April 12, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks releases an investor podcast for biotech traders and investors with a company spotlight on a small biotech company making headway in the diabetes and obesity market with its core technology.
Sirona Biochem Corp (TSX-V: SBM , OTC: SRBCF), is a company using Carbohydrate-based molecules to develop Sodium Glucose Transporter (SGLT) inhibitors for Type 2 diabetes and obesity as one of its key products in its pipeline.
Listen to Podcast
About Sirona Biochem Corp (www.sironabiochem.com)
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Research biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure- Investorideas.com and its affiliate news and email partners were compensated six thousand for news distribution and publishing online and to optin subscribers
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com
Biotech Company Develops Promising Potential Treatment for Type 2 Diabetes and Obesity
New York, New York - April 12, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a biotech company snapshot for Sirona Biochem Corp. ( TSX-V: SBM , OTC: SRBCF, Frankfurt: ZSB), a company using arbohydrate-based molecules to develop Sodium Glucose Transporter (SGLT) inhibitors for Type 2 diabetes and obesity as one of its key products in its pipeline.
The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules.
Sodium Glucose Transporter (SGLT) Inhibitors - Diabetes & Obesity
Sirona Biochem is developing SGLT inhibitors for Type 2 diabetes and obesity. SGLT inhibitors are a new class of drugs for diabetes and obesity. They work differently from traditional Type 2 diabetes therapeutics which increase insulin production in the pancreas and affect metabolism. In the kidneys, SGLT inhibitors reduce the reabsorption of glucose into the bloodstream by eliminating excess glucose into the urine.
The kidneys filter approximately 180 gm of glucose per day from the blood which is then mostly reabsorbed back into the blood by SGLT transporters. SGLT inhibitors reduce the glucose reabsorption process, such that excess glucose is excreted in the urine, rather than reabsorbed into the bloodstream. That is to say, they can help regulate glycemia. This is a new promising potential treatment for Type 2 diabetes and obesity.
Status & Milestones
Preclinical animal tests of Sirona Biochem's SGLT inhibitor for Type 2 diabetes are well underway with the positive results posted in the first quarter of 2011. Additional preclinical studies to test the safety and toxicology of this SGLT inhibitor are currently being conducted. Sirona Biochem plans to independently complete preclinical studies to prepare its SGLT inhibitor for human clinical trials. A pharmaceutical partner will be sought for clinical and commercial development of our program.
Watch the video on SBM's technology - how it works:
http://www.youtube.com/watch?feature=player_embedded&v=F_fAzxsf7hk
About Sirona Biochem Corp (www.sironabiochem.com)
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Research biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure - Investorideas.com and its affiliate news and email partners were compensated six thousand for news distribution and publishing online and to optin subscribers
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com
New York, New York - April 12, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a biotech company snapshot for Sirona Biochem Corp. ( TSX-V: SBM , OTC: SRBCF, Frankfurt: ZSB), a company using arbohydrate-based molecules to develop Sodium Glucose Transporter (SGLT) inhibitors for Type 2 diabetes and obesity as one of its key products in its pipeline.
The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules.
Sodium Glucose Transporter (SGLT) Inhibitors - Diabetes & Obesity
Sirona Biochem is developing SGLT inhibitors for Type 2 diabetes and obesity. SGLT inhibitors are a new class of drugs for diabetes and obesity. They work differently from traditional Type 2 diabetes therapeutics which increase insulin production in the pancreas and affect metabolism. In the kidneys, SGLT inhibitors reduce the reabsorption of glucose into the bloodstream by eliminating excess glucose into the urine.
The kidneys filter approximately 180 gm of glucose per day from the blood which is then mostly reabsorbed back into the blood by SGLT transporters. SGLT inhibitors reduce the glucose reabsorption process, such that excess glucose is excreted in the urine, rather than reabsorbed into the bloodstream. That is to say, they can help regulate glycemia. This is a new promising potential treatment for Type 2 diabetes and obesity.
Status & Milestones
Preclinical animal tests of Sirona Biochem's SGLT inhibitor for Type 2 diabetes are well underway with the positive results posted in the first quarter of 2011. Additional preclinical studies to test the safety and toxicology of this SGLT inhibitor are currently being conducted. Sirona Biochem plans to independently complete preclinical studies to prepare its SGLT inhibitor for human clinical trials. A pharmaceutical partner will be sought for clinical and commercial development of our program.
Watch the video on SBM's technology - how it works:
http://www.youtube.com/watch?feature=player_embedded&v=F_fAzxsf7hk
About Sirona Biochem Corp (www.sironabiochem.com)
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Research biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure - Investorideas.com and its affiliate news and email partners were compensated six thousand for news distribution and publishing online and to optin subscribers
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com
Wednesday, April 11, 2012
Biotech Stock to Watch: Sirona Biochem (TSX-V: SBM, OTC: SRBCF, Frankfurt: ZSB)
New York, New York - April 11, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a biotech investor spotlight for Sirona Biochem Corp . (TSX-V: SBM, OTC: SRBCF, Frankfurt: ZSB).
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules.
Investor video on SBM's technology!
Read the previous news release. SBM just closed a private placement of over $1 Million dollars!
http://www.sironabiochem.com/sirona-closes-non-brokered-private-placement-of-1406500/
Today's News:
Sirona Biochem Corp. (TSX-V: SBM, OTC: SRBCF, Frankfurt: ZSB), announced today its abstract application to present a scientific poster at the 2012 Protein Engineering Summit (PEGS) has been accepted. Sirona Biochems scientific poster has been selected to be on display during the Difficult to Express Proteins track April 30 to May 1, 2012.
The Eighth Annual PEGS conference, to be held April 30 May 4, 2012 in Boston, MA, brings together an estimated 1,400 international decision makers in pharmaceutical, biotechnology, academia and public healthcare and focuses on the latest scientific innovations in protein engineering.
Sirona Biochems scientific poster at the PEGS conference will describe the use of its new inducer, SBM-TFC-358, and how it may be effective at improving recombinant protein yields. The poster will also include results from the latest study demonstrating the effectiveness of SBM-TFC-358 on a recalcitrant protein and comparing the compound against a widely used inducer, IPTG.
Additional studies are being conducted to further characterize SBM-TFC-358 and prepare it for commercialization.
A copy of the poster will be made available on the companys website at www.sironabiochem.com after the conference.
About Sirona Biochem Corpwww.sironabiochem.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Research biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure- Investorideas.com and its affiliate news and email partners were compensated six thousand for news distribution and publishing online and to optin subscribers
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com
New York, New York - April 11, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a biotech investor spotlight for Sirona Biochem Corp . (TSX-V: SBM, OTC: SRBCF, Frankfurt: ZSB).
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules.
Investor video on SBM's technology!
Read the previous news release. SBM just closed a private placement of over $1 Million dollars!
http://www.sironabiochem.com/sirona-closes-non-brokered-private-placement-of-1406500/
Today's News:
Sirona Biochem Corp. (TSX-V: SBM, OTC: SRBCF, Frankfurt: ZSB), announced today its abstract application to present a scientific poster at the 2012 Protein Engineering Summit (PEGS) has been accepted. Sirona Biochems scientific poster has been selected to be on display during the Difficult to Express Proteins track April 30 to May 1, 2012.
The Eighth Annual PEGS conference, to be held April 30 May 4, 2012 in Boston, MA, brings together an estimated 1,400 international decision makers in pharmaceutical, biotechnology, academia and public healthcare and focuses on the latest scientific innovations in protein engineering.
Sirona Biochems scientific poster at the PEGS conference will describe the use of its new inducer, SBM-TFC-358, and how it may be effective at improving recombinant protein yields. The poster will also include results from the latest study demonstrating the effectiveness of SBM-TFC-358 on a recalcitrant protein and comparing the compound against a widely used inducer, IPTG.
Additional studies are being conducted to further characterize SBM-TFC-358 and prepare it for commercialization.
A copy of the poster will be made available on the companys website at www.sironabiochem.com after the conference.
About Sirona Biochem Corpwww.sironabiochem.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Research biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure- Investorideas.com and its affiliate news and email partners were compensated six thousand for news distribution and publishing online and to optin subscribers
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com
Mining Stocks; YALE (TSX-V: YLL) Reports On AGM
VANCOUVER, British Columbia - April 11, 2012 (Investorideas.com Mining stocks Newswire) - Yale Resources Ltd. (TSX-V: YLL, OTCBB: YRLLF, and Frankfurt: YAB) is pleased to report that all resolutions were passed at its Annual General Meeting held on April 10, 2012. The Board of Directors and management would like to thank all shareholders for their support and confidence.
"In these difficult markets it is reassuring to have the support of a core group of shareholders who understand that Yale's business model has shown considerable growth over last year and that we have the potential to significantly advance at least three of our projects in the coming 6 to 8 months with projected expenditures by our optionees to be approximately $1,000,000", stated Ian Foreman, P.Geo., president of Yale.
The Board of Directors and Officers for the upcoming year will consist of:
"Ian Foreman"
Ian Foreman, P.Geo.
President
For additional information on Yale Resources please call the Company at 604-678-2531.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Statements in this press release, other than purely historical information, including statements relating to the Company's future plans and objectives or expected results, may include forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in resource exploration and development. As a result, actual results may vary materially from those described in the forward-looking statements.
Contact:
Yale Resources Ltd.
400 - 409 Granville St.,
Vancouver, BC, Canada V6C 1T2
News Release #12-4
Ian Foreman
604-678-2531
VANCOUVER, British Columbia - April 11, 2012 (Investorideas.com Mining stocks Newswire) - Yale Resources Ltd. (TSX-V: YLL, OTCBB: YRLLF, and Frankfurt: YAB) is pleased to report that all resolutions were passed at its Annual General Meeting held on April 10, 2012. The Board of Directors and management would like to thank all shareholders for their support and confidence.
"In these difficult markets it is reassuring to have the support of a core group of shareholders who understand that Yale's business model has shown considerable growth over last year and that we have the potential to significantly advance at least three of our projects in the coming 6 to 8 months with projected expenditures by our optionees to be approximately $1,000,000", stated Ian Foreman, P.Geo., president of Yale.
The Board of Directors and Officers for the upcoming year will consist of:
- Ian Foreman, P.Geo. - President, Director and Audit Committee Member
- Lindsay Bottomer, P.Geo - Director
- David Hall - Director and Audit Committee Chair
- Edmundo Uribe - Director and Audit Committee Member
- Ezra Jimenez, LLM, MBA - Vice President - Operations and CFO
"Ian Foreman"
Ian Foreman, P.Geo.
President
For additional information on Yale Resources please call the Company at 604-678-2531.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Statements in this press release, other than purely historical information, including statements relating to the Company's future plans and objectives or expected results, may include forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in resource exploration and development. As a result, actual results may vary materially from those described in the forward-looking statements.
Contact:
Yale Resources Ltd.
400 - 409 Granville St.,
Vancouver, BC, Canada V6C 1T2
News Release #12-4
Ian Foreman
604-678-2531
Visit the YLL showcase profile at Investorideas.com
Request News and Info on YLL
Disclosure, Disclaimer/ Investorideas.com is paid by YLL to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs (five hundred per month)
Request News and Info on YLL
Disclosure, Disclaimer/ Investorideas.com is paid by YLL to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs (five hundred per month)
Social Media Stocks Snapshot Investor Podcast
This is an Investorideas.com podcast for social networking stocks, for trading as of April 10th
Listen to Podcast
Research Social Networking stocks:
Visit the Investorideas.com Social Networking Stocks Directory preview page:
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter
Follow Investorideas.com on Facebook
Sign up for the free investor news letter and stock alerts at Investorideas.com
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure- Investorideas.com and its affiliate news and email partners was compensated three thousand for the distribution and publication of LAST company news unrelated to this podcast
Qwww.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
This is an Investorideas.com podcast for social networking stocks, for trading as of April 10th
Listen to Podcast
Research Social Networking stocks:
Visit the Investorideas.com Social Networking Stocks Directory preview page:
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter
Follow Investorideas.com on Facebook
Sign up for the free investor news letter and stock alerts at Investorideas.com
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure- Investorideas.com and its affiliate news and email partners was compensated three thousand for the distribution and publication of LAST company news unrelated to this podcast
Qwww.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Gold Stocks; Gold Bullion Development Corp. (TSX-V: GBB) - Shareholder Gold Royalty Program
VANCOUVER - April 11, 2012 (Investorideas.com Mining stocks Newswire) - Gold Bullion Development Corp. (TSXV: GBB, OTC PINK: GBBFF) (the "Company" or "Gold Bullion") is pleased to provide an update with respect to its proposed Shareholder Gold Royalty Program.
The Shareholder Gold Royalty is being developed so that Gold Bullion shareholders can participate in the security of gold ownership. The proposed Shareholder Gold Royalty is intended to allow Gold Bullion shareholders to receive a dividend payable in gold on a pro rata basis, based on the number of Gold Bullion shares held on the dividend record date. Shareholders who do not have a gold metal account or for other reason may not be able to receive the physical metal will be able to receive their dividend in Canadian dollars.
Gold Bullion intends to implement the Shareholder Gold Royalty if and when the Granada Gold Mine enters into production. The Shareholder Gold Royalty will be for the life of the Granada Gold Mine for all current resources, and for other resources that may be discovered through further exploration. Gold Bullion cannot guarantee that the Granada Gold Mine will enter into production or that the proposed Shareholder Gold Royalty will be implemented. The proposed Shareholder Gold Royalty replaces the Shareholder Gold Purchase Program outlined in Gold Bullion's news release dated June 4 th, 2008, and is part of Gold Bullion's forward-looking policy of ensuring shareholder value. Gold Bullion will inform shareholders of the details of the Shareholder Gold Royalty as the program is developed.
About Gold Bullion Development Corp.
Gold Bullion Development Corp. is a TSX Venture-listed junior natural resource company focusing on the exploration and development of its Granada Property near Rouyn-Noranda, Qu�bec. Additional information on the company's Granada gold property is available by visiting their website at www.GoldBullionDevelopmentCorp.com and on SEDAR.com.
"Frank J. Basa"
Frank J. Basa, P.Eng.
President and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
VANCOUVER - April 11, 2012 (Investorideas.com Mining stocks Newswire) - Gold Bullion Development Corp. (TSXV: GBB, OTC PINK: GBBFF) (the "Company" or "Gold Bullion") is pleased to provide an update with respect to its proposed Shareholder Gold Royalty Program.
The Shareholder Gold Royalty is being developed so that Gold Bullion shareholders can participate in the security of gold ownership. The proposed Shareholder Gold Royalty is intended to allow Gold Bullion shareholders to receive a dividend payable in gold on a pro rata basis, based on the number of Gold Bullion shares held on the dividend record date. Shareholders who do not have a gold metal account or for other reason may not be able to receive the physical metal will be able to receive their dividend in Canadian dollars.
Gold Bullion intends to implement the Shareholder Gold Royalty if and when the Granada Gold Mine enters into production. The Shareholder Gold Royalty will be for the life of the Granada Gold Mine for all current resources, and for other resources that may be discovered through further exploration. Gold Bullion cannot guarantee that the Granada Gold Mine will enter into production or that the proposed Shareholder Gold Royalty will be implemented. The proposed Shareholder Gold Royalty replaces the Shareholder Gold Purchase Program outlined in Gold Bullion's news release dated June 4 th, 2008, and is part of Gold Bullion's forward-looking policy of ensuring shareholder value. Gold Bullion will inform shareholders of the details of the Shareholder Gold Royalty as the program is developed.
About Gold Bullion Development Corp.
Gold Bullion Development Corp. is a TSX Venture-listed junior natural resource company focusing on the exploration and development of its Granada Property near Rouyn-Noranda, Qu�bec. Additional information on the company's Granada gold property is available by visiting their website at www.GoldBullionDevelopmentCorp.com and on SEDAR.com.
"Frank J. Basa"
Frank J. Basa, P.Eng.
President and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
Visit the GBB showcase profile at Investorideas.com
Request News and Info on GBB
Disclosure, Disclaimer/ GBB is a paid advertising client on Investorideas.com and our mining portals.
Disclosure, Disclaimer/ Investorideas.com is paid by GBB to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs (five hundred per month)
Request News and Info on GBB
Disclosure, Disclaimer/ GBB is a paid advertising client on Investorideas.com and our mining portals.
Medical Technology Stock Alert; PositiveID Corporation (OTCBB:PSID) Begins Orders of iglucose at www.iglucose.com
DELRAY BEACH, Fla. - April 11, 2012 (Investorideas.com newswire) - PositiveID Corporation (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense, today announced it has begun taking orders of its FDA-cleared iglucose(R) mobile health system for diabetes management. Pre-orders are being accepted through the iglucose website at www.iglucose.com and the PositiveID website at www.positiveidcorp.com. PositiveID expects to commercially launch iglucose during the second quarter of 2012.
Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner
PositiveID's FDA-cleared iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By seamlessly communicating blood glucose readings from glucometers to the iglucose diabetes management portal, glucose readings can be shared with family members and healthcare professionals, making it possible to improve care in a cost-effective manner. iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. iglucose does not require the use of a cell phone or a wireless plan.
"As we complete the final stages of preparing for the commercial launch of iglucose, we are pleased, based on consumer demand, to be able to provide the opportunity to pre-order this FDA-cleared system for diabetes management," stated William J. Caragol, Chairman and CEO of PositiveID. "Those who order will be given priority status while we initially roll-out iglucose through pilot programs with health insurers and home-healthcare providers."
The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan(R), Abbott FreeStyle(R), Bayer Contour (R), and Nipro Diagnostic(TM) True(TM) monitoring systems to a secure database via wireless cellular technology. The Company is continually adding to this list of supported glucose meters. For more information on iglucose, visit www.iglucose.com.
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
DELRAY BEACH, Fla. - April 11, 2012 (Investorideas.com newswire) - PositiveID Corporation (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense, today announced it has begun taking orders of its FDA-cleared iglucose(R) mobile health system for diabetes management. Pre-orders are being accepted through the iglucose website at www.iglucose.com and the PositiveID website at www.positiveidcorp.com. PositiveID expects to commercially launch iglucose during the second quarter of 2012.
Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner
PositiveID's FDA-cleared iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By seamlessly communicating blood glucose readings from glucometers to the iglucose diabetes management portal, glucose readings can be shared with family members and healthcare professionals, making it possible to improve care in a cost-effective manner. iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. iglucose does not require the use of a cell phone or a wireless plan.
"As we complete the final stages of preparing for the commercial launch of iglucose, we are pleased, based on consumer demand, to be able to provide the opportunity to pre-order this FDA-cleared system for diabetes management," stated William J. Caragol, Chairman and CEO of PositiveID. "Those who order will be given priority status while we initially roll-out iglucose through pilot programs with health insurers and home-healthcare providers."
The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan(R), Abbott FreeStyle(R), Bayer Contour (R), and Nipro Diagnostic(TM) True(TM) monitoring systems to a secure database via wireless cellular technology. The Company is continually adding to this list of supported glucose meters. For more information on iglucose, visit www.iglucose.com.
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Wind Stock News: Clean Wind Energy Tower, Inc. (OTCBB:CWET) Receives San Luis Planning Commission's Recommendation for Downdraft Tower
ANNAPOLIS, Md. - April 11, 2012 (Investorideas.com renewable energy/green newswire) Clean Wind Energy Tower, Inc. (OTCBB:CWET) (the "Company") announced today that on April 10th, 2012 the City of San Luis, Arizona Planning Commission held a hearing to discuss Clean Wind Energy's application to build an innovative green renewable energy Downdraft Tower Facility within the San Luis City limits. At this hearing the Planning Commission voted in favor of the Downdraft Tower. The San Luis City Council has scheduled a hearing on the Project to be held on May 9th, 2012.
The San Luis location incorporates plans for two (2) Downdraft Towers and a component parts Assembly Plant. As designed, the Company anticipates that each Downdraft Tower could generate enough electricity to power up to 1,600,000 homes using the guidelines set forth in the California Statewide Residential Appliance Saturation Study, 2004. As an independent power producer of clean renewable energy, the Company will not be selling power directly to consumers but rather to the grid.
The Company believes that San Luis is an ideal location for their alternative energy facility because this region of the southwest United States provides the proper weather profiles, proximity to the power grid, and other ingredients beneficial to the operation of a Downdraft Tower, and has been previously targeted as a prime region for alternative energy projects. The Downdraft Tower is a breakthrough source of clean alternative energy, and will bring significant employment opportunities and economic stimulus to San Luis and a number of U.S. industries. Clean Wind Energy anticipates that during the Downdraft Tower's construction phase, 2,500 construction and transportation jobs and 1,000 manufacturing jobs will be created. Once placed in service, each Tower should generate 1,000 permanent jobs.
About Clean Wind Energy, Inc.
Clean Wind Energy, Inc., a wholly owned subsidiary of Clean Wind Energy Tower, Inc., has designed and is preparing to develop, and construct large "Downdraft Towers" that use benevolent, non-toxic natural elements to generate electricity and clean water economically by integrating and synthesizing numerous proven as well as emerging technologies.
The Company's core objective and focus is to become a provider of clean efficient green energy to the world communities at a reasonable cost without the destructive residuals of fossil fuel, and to help broker the chasm between both, while continuing to generate innovative technological solutions for today and tomorrow's electrical power needs.
In addition to constructing Downdraft Towers in the United States and abroad, the Company intends to establish partnerships at home and abroad to propagate these systems and meet increasing global demand for clean water and electricity. Clean Wind has assembled a team of experienced business professionals, engineers and scientists with access to the breakthrough energy research upon which this technology is founded and the proven ability to bring the idea to market. Clean Wind Energy, Inc. has filed several patents that the Company believes will further enhance this potentially revolutionary technology. Clean Wind Energy, Inc. is based in Annapolis MD, and is traded on the OTCBB under the symbol 'CWET'. For more information visit www.cleanwindenergytower.com
Contact:
Clean Wind Energy, Inc.
1997 Annapolis Exchange Parkway Suite 300
Annapolis, Maryland 21401
Phone: 410-972-4713
E-mail: Info@cwetower.com
www.cleanwindenergytower.com
Investor Relations Contact:
Jody Janson
Phone: (855) 848-6937
Email: ir@cwetower.com
Cautionary Note Regarding Forward-Looking Statements
Statements included in this release may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential factors that could affect the Company's financial results, can be found in the Company's various filings with the Securities and Exchange Commission (SEC).
Visit the CWET showcase page at Investorideas.com:
http://www.investorideas.com/CO/CWE/
Research more wind stocks with the renewable energy stocks directory:
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor alerts including news on wind stocks
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) publishing program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one thousand per month to publish news and updates on the company on Investorideas.com newswire and blogs . Investorideas.com owns 150,000 shares of 144 stock .Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dvanzant@investorideas.com or cvanzant@investorideas.com
ANNAPOLIS, Md. - April 11, 2012 (Investorideas.com renewable energy/green newswire) Clean Wind Energy Tower, Inc. (OTCBB:CWET) (the "Company") announced today that on April 10th, 2012 the City of San Luis, Arizona Planning Commission held a hearing to discuss Clean Wind Energy's application to build an innovative green renewable energy Downdraft Tower Facility within the San Luis City limits. At this hearing the Planning Commission voted in favor of the Downdraft Tower. The San Luis City Council has scheduled a hearing on the Project to be held on May 9th, 2012.
The San Luis location incorporates plans for two (2) Downdraft Towers and a component parts Assembly Plant. As designed, the Company anticipates that each Downdraft Tower could generate enough electricity to power up to 1,600,000 homes using the guidelines set forth in the California Statewide Residential Appliance Saturation Study, 2004. As an independent power producer of clean renewable energy, the Company will not be selling power directly to consumers but rather to the grid.
The Company believes that San Luis is an ideal location for their alternative energy facility because this region of the southwest United States provides the proper weather profiles, proximity to the power grid, and other ingredients beneficial to the operation of a Downdraft Tower, and has been previously targeted as a prime region for alternative energy projects. The Downdraft Tower is a breakthrough source of clean alternative energy, and will bring significant employment opportunities and economic stimulus to San Luis and a number of U.S. industries. Clean Wind Energy anticipates that during the Downdraft Tower's construction phase, 2,500 construction and transportation jobs and 1,000 manufacturing jobs will be created. Once placed in service, each Tower should generate 1,000 permanent jobs.
About Clean Wind Energy, Inc.
Clean Wind Energy, Inc., a wholly owned subsidiary of Clean Wind Energy Tower, Inc., has designed and is preparing to develop, and construct large "Downdraft Towers" that use benevolent, non-toxic natural elements to generate electricity and clean water economically by integrating and synthesizing numerous proven as well as emerging technologies.
The Company's core objective and focus is to become a provider of clean efficient green energy to the world communities at a reasonable cost without the destructive residuals of fossil fuel, and to help broker the chasm between both, while continuing to generate innovative technological solutions for today and tomorrow's electrical power needs.
In addition to constructing Downdraft Towers in the United States and abroad, the Company intends to establish partnerships at home and abroad to propagate these systems and meet increasing global demand for clean water and electricity. Clean Wind has assembled a team of experienced business professionals, engineers and scientists with access to the breakthrough energy research upon which this technology is founded and the proven ability to bring the idea to market. Clean Wind Energy, Inc. has filed several patents that the Company believes will further enhance this potentially revolutionary technology. Clean Wind Energy, Inc. is based in Annapolis MD, and is traded on the OTCBB under the symbol 'CWET'. For more information visit www.cleanwindenergytower.com
Contact:
Clean Wind Energy, Inc.
1997 Annapolis Exchange Parkway Suite 300
Annapolis, Maryland 21401
Phone: 410-972-4713
E-mail: Info@cwetower.com
www.cleanwindenergytower.com
Investor Relations Contact:
Jody Janson
Phone: (855) 848-6937
Email: ir@cwetower.com
Cautionary Note Regarding Forward-Looking Statements
Statements included in this release may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential factors that could affect the Company's financial results, can be found in the Company's various filings with the Securities and Exchange Commission (SEC).
Visit the CWET showcase page at Investorideas.com:
http://www.investorideas.com/CO/CWE/
Research more wind stocks with the renewable energy stocks directory:
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor alerts including news on wind stocks
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) publishing program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one thousand per month to publish news and updates on the company on Investorideas.com newswire and blogs . Investorideas.com owns 150,000 shares of 144 stock .Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dvanzant@investorideas.com or cvanzant@investorideas.com
Biotech Investor Alert: Sirona Biochem (TSX-V: SBM) to Present Scientific Poster of Inducer Program at 2012 Protein Engineering Summit (PEGS)
Vancouver, British Columbia - April 11, 2012 (InvestorIdeas.com Newswire) Sirona Biochem Corp. ( TSX-V: SBM , OTC: SRBCF, Frankfurt: ZSB), announced today its abstract application to present a scientific poster at the 2012 Protein Engineering Summit (PEGS) has been accepted. Sirona Biochem's scientific poster has been selected to be on display during the “Difficult to Express Proteins” track April 30 to May 1, 2012.
The Eighth Annual PEGS conference, to be held April 30 - May 4, 2012 in Boston, MA, brings together an estimated 1,400 international decision makers in pharmaceutical, biotechnology, academia and public healthcare and focuses on the latest scientific innovations in protein engineering.
Sirona Biochem's scientific poster at the PEGS conference will describe the use of its new inducer, SBM-TFC-358, and how it may be effective at improving recombinant protein yields. The poster will also include results from the latest study demonstrating the effectiveness of SBM-TFC-358 on a recalcitrant protein and comparing the compound against a widely used inducer, IPTG.
Additional studies are being conducted to further characterize SBM-TFC-358 and prepare it for commercialization.
A copy of the poster will be made available on the company's website at www.sironabiochem.com after the conference.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone: 604.282.6065
Email: jjang@sironabiochem.com
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Published at the Investorideas.com Newswire
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure- Investorideas.com and its affiliate news and email partners were compensated six thousand for news distribution and publishing online and to optin subscribers
Vancouver, British Columbia - April 11, 2012 (InvestorIdeas.com Newswire) Sirona Biochem Corp. ( TSX-V: SBM , OTC: SRBCF, Frankfurt: ZSB), announced today its abstract application to present a scientific poster at the 2012 Protein Engineering Summit (PEGS) has been accepted. Sirona Biochem's scientific poster has been selected to be on display during the “Difficult to Express Proteins” track April 30 to May 1, 2012.
The Eighth Annual PEGS conference, to be held April 30 - May 4, 2012 in Boston, MA, brings together an estimated 1,400 international decision makers in pharmaceutical, biotechnology, academia and public healthcare and focuses on the latest scientific innovations in protein engineering.
Sirona Biochem's scientific poster at the PEGS conference will describe the use of its new inducer, SBM-TFC-358, and how it may be effective at improving recombinant protein yields. The poster will also include results from the latest study demonstrating the effectiveness of SBM-TFC-358 on a recalcitrant protein and comparing the compound against a widely used inducer, IPTG.
Additional studies are being conducted to further characterize SBM-TFC-358 and prepare it for commercialization.
A copy of the poster will be made available on the company's website at www.sironabiochem.com after the conference.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone: 604.282.6065
Email: jjang@sironabiochem.com
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Published at the Investorideas.com Newswire
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure- Investorideas.com and its affiliate news and email partners were compensated six thousand for news distribution and publishing online and to optin subscribers
Subscribe to:
Posts (Atom)